New Twelve-Sample Product Will Enable Researchers to Combine DNA and RNA Research at a Substantially Lower Cost SAN DIEGO–Illumina, Inc., (NASDAQ:ILMN – News) at its Annual North American User Group Meeting, introduced the HumanHT-12 BeadChip, a twelve sample product designed to accelerate whole genome expression and expression-based Quantitative Trait Loci (eQTL) studies. The HumanHT-12 BeadChip includes over 48,000 probes per sample and is priced at $75, supporting a total cost of $100 per sample including labeling reagents. Illumina expects to commence shipment of this new product in the second quarter 2008. “The HumanHT-12 BeadChip is a powerful new product that will enable high-throughput whole-genome expression and eQTL analysis at exceptional price points. Along with the HumanWG-6, which offers the industry’s highest quality whole-genome expression data, the HumanHT-12 will provide gene expression researchers with the most flexible and cost effective screening tool,” said Tristan Orpin, Illumina’s Senior Vice President of Commercial Operations. “Additionally, the HumanHT-12 will allow researchers to enhance their genomics studies by the economical addition of eQTL data. The ability to cost effectively complement large-scale genotyping studies with gene expression profiles will allow researchers to gain additional important insights into the relationship between genotypes and phenotypic profiles.” The introduction of the HumanHT-12 BeadChip further enhances Illumina’s suite of gene expression products, which includes sequencing-based assays for discovery and typing of transcripts, alternative splice forms, and small and microRNA’s, and array-based assays for rapid and cost effective profiling of expression in human, rat, and mouse. The new HumanHT-12 BeadChip provides the same content as that of the HumanWG-6 BeadChip, and researchers using the HumanHT-12 can expect to measure data from greater than 99.99 percent of the probe sets for each sample. To accelerate the use of the HumanHT-12 as a component of genotyping studies, Illumina will offer special pricing to customers ordering both its Infinium Genotyping BeadChips and its HumanHT-12 BeadChips. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.